Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, BENITEC BIOPHARMA INC. reported revenue of $0M, down 100.0% year over year. Operating margin was n/a and net margin n/a, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from BNTC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $0M | n/a | n/a |
| FY2023 | $0M | -25441.3% | -26082.7% |
| FY2022 | $0M | -24457.5% | -24942.5% |
| FY2021 | $0M | -23044.1% | -23528.8% |
| FY2020 | $0M | -8118.6% | -8111.8% |
How does BNTC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.